Premium
The Parkinson disease‐associated A30P mutation stabilizes α‐synuclein against proteasomal degradation triggered by heme oxygenase‐1 over‐expression in human neuroblastoma cells
Author(s) -
Song Wei,
Patel Amar,
Qureshi Hamid Y.,
Han Dong,
Schipper Hyman M.,
Paudel Hemant K.
Publication year - 2009
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2009.06165.x
Subject(s) - heme oxygenase , biliverdin , alpha synuclein , heme , biliverdin reductase , intracellular , chemistry , lactacystin , proteasome , mg132 , protein degradation , microbiology and biotechnology , transfection , proteasome inhibitor , biology , biochemistry , medicine , parkinson's disease , enzyme , gene , disease
Proteosomal degradation of proteins is one of the major mechanisms of intracellular protein turnover. Failure of the proteosome to degrade misfolded protein is implicated in the accumulation of α‐synuclein in Parkinson’s disease (PD). Heme oxygenase‐1 (HO‐1), an enzyme that converts heme to free iron, carbon monoxide (CO) and biliverdin (bilirubin precursor) is expressed in response to various stressors. HO‐1 is up‐regulated in PD‐ and Alzheimer’s disease‐affected neural tissues. In this study, we found that HO‐1 over‐expression engenders dose‐dependent decreases in α‐synuclein protein levels in human neuroblastoma M17 cells. When over‐expression of HO‐1 was silenced in HO‐1 transfected cells, level of α‐synuclein was restored. Likewise, treatment of HO‐1 over‐expressing cells with the HO‐1 inhibitor, tin mesoporphyrin, the iron chelator deferoxamine or antagonist of CO‐dependent cGMP activation, methylene blue, mitigated the HO‐1‐induced reduction in α‐synuclein levels. Furthermore, when HO‐1 over‐expressing cells were treated with the proteosome inhibitors, lactacystin and MG132, level of α‐synuclein was almost completely restored. In contrast to the effect on α‐synuclein [wild‐type (WT)] levels, HO‐1 over‐expression did not significantly impact PD‐associated α‐synuclein (A30P) levels in these cells. HO‐1 also significantly reduced aggregation of α‐synuclein (WT) but not that of A30P. Our results suggest that HO‐1, which is expressed when neurons are exposed to toxic stimuli capable of inducing protein misfolding, triggers proteosomal degradation of proteins and prevents intracellular accumulation of protein aggregates and inclusions. Resistance to HO‐1 induced proteosomal degradation may render the familial PD‐associated A30P mutation prone to toxic intracellular aggregation.